<?xml version="1.0" encoding="UTF-8"?>
<p id="p0195">
 <xref rid="bib41" ref-type="bibr">Maes et al. (1996)</xref> found that chlorpromazine lower DPP 4 activity in major depression and higher DPP 4 activity in schizophrenia patients than in normal volunteers in contrast to 
 <xref rid="bib7" ref-type="bibr">Chikuma et al. (1987)</xref>. Subchronic use of antidepressants or antipsychotic agents (perphenazine 8–48 mg/day) does not have an influence on the alterations in DPP 4 is depressed (33.6 ± 10.4 U/l before treatment and 37.5 ± 9.0 U/l after treatment) or schizophrenic patients (44.8 ± 9.1 U/l before treatment and 45.6 ± 10.2 U/l after treatment), respectively (
 <xref rid="bib41" ref-type="bibr">Maes et al., 1996</xref>). It suggests that perphenazine is a much better candidate against MERS-CoV.
</p>
